N/A
Completed N=25
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
Source: ClinicalTrials.gov NCT00195338 ↗Enrolled (actual)
25
Serious AEs
24.0%
Results posted
Jan 2012
Primary outcomePrimary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 56; 24 percentage of participants
Summary
The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients. All patients initiated with Enbrel will be observed from the start of the study in Feb 2003 for a period of at least 5 years.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |
56; 24 | — |
| SECONDARY Percentage of Participants With Completion of Study Treatment |
100; 100; 92; 80; 80; 80 | — |
| SECONDARY Change From Baseline in Number of Joints With Active Synovitis at Months 6, 12, 18, 30, 42, 54 and 66 |
26.5; -20.2; -20.3; -21.4; -19.5; -24.4 | — |
| SECONDARY Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Months 6, 12, 18, 30, 42, 54 and 66 |
32.4; -13.7; -17.0; -17.8; -10.4; -20.0 | — |
| SECONDARY Mean Dose of Concomitant Methotrexate (MTX) and Steroids |
— | — |
Eligibility Criteria
Inclusion Criteria
- Have moderate to severe active rheumatoid arthritis
- Be aged of 17 years or more
- Have inadequate response to DMards
- Give written informed consent
- Physician decides to prescribe Enbrel
Exclusion Criteria
n/a
Data sourced from ClinicalTrials.gov (NCT00195338). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.